ClinicalTrials.gg
RecruitingNCT05789485Updated Aug 25, 2026

A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers

A Phase 2 interventional study of structured treadmill walking in Gastrointestinal Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 316 studies in Gastrointestinal Neoplasms with a site in United States — 83 open to participants now, 116 under way, 4 of them phase 3. Gastrointestinal Neoplasms · United States.

Planned enrollment
48th of 245
216 · median 60
Started
2023
with 24 others
Phase 2
42 of 316
8 open now
Primary completion
2027-03
later than 41 of 113 live
Registered
246th of 316
by date
Lead sponsor
6 of 316
Memorial Sloan Kettering Cancer Center

Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, this one is the 48th largest by planned enrollment of the 245 interventional ones that give a count, is one of 25 that started in 2023, is one of 42 in phase 2, reaches primary completion later than 41 of the 113 other live ones, and was the 246th registered.

Gastrointestinal Neoplasms

698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

83 of the 316 studies in Gastrointestinal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 316 studies in Gastrointestinal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to find the level of aerobic exercise (AT) that is practical, is safe, and has positive effects on the body that may reduce the side effects of therapy. The study will also look at the way the body responds to exercise and whether there are differences in treatment. This will include looking at the highest treatment dose participants receive, how many people stop, delay, or reduce the treatment, and whether additional medication is needed to treat side effects of therapy.

Read the detailed description

Study staff will also confirm remote training feasibility including items such as access to Wi-Fi and a treadmill for the study duration. If patients do not have access to a treadmill, ExOnc staff may coordinate access to a fitness facility local to the participant, to facilitate treadmill access for the study duration. Fitness facility access will be provided through Wellhub, a service that allows use of nearby gyms and studios through a single app-based solution.

03

Conditions studied

  • Gastrointestinal Cancer

Keywords

  • Exercise
  • 22-164
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years
  • Diagnosed with colorectal or esophago/gastric solid tumors as defined by one of the following:

    • Histological confirmation
    • As per standard of care imaging
  • Scheduled to receive chemotherapy or chemotherapy for newly diagnosed disease
  • Performing ≤90 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluated by self-report
  • Willingness to comply with all study-related procedures
  • Cleared for exercise participation as per screening clearance via the Physical Activity Readiness Questionnaire

Exclusion criteria

Exclusion Criteria:

  • Enrollment onto any other lifestyle interventional study, except interventions determined by the PI not to confound study outcomes
  • Receiving treatment for any other diagnosis of invasive cancer
  • Mental impairment leading to inability to cooperate
  • Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
216 participants (estimated)

Study arms

  • Experimental
    90 min/wk

    AT will consist of individualized walking delivered up to 7 times per week to achieve a cumulative total duration of: Arm 1: 90 min/wk. AT therapy within each arm will follow a non-linear (i.e., AT dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule delivered during chemotherapy. Supervised AT will be monitored using TeleEx.

    Behavioral: structured treadmill walking

  • Experimental
    150 mins/wk

    AT will consist of individualized walking delivered up to 7 times per week to achieve a cumulative total duration of: Arm 2: 150 min/wk. AT therapy within each arm will follow a non-linear (i.e., AT dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule delivered during chemotherapy. Supervised AT will be monitored using TeleEx.

    Behavioral: structured treadmill walking

  • Experimental
    300 mins/wk

    AT will consist of individualized walking delivered up to 7 times per week to achieve a cumulative total duration of: Arm 3: 300 min/wk. AT therapy within each arm will follow a non-linear (i.e., AT dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule delivered during chemotherapy. Supervised AT will be monitored using TeleEx.

    Behavioral: structured treadmill walking

Interventions

  • Behavioralstructured treadmill walking

    Three doses of AT (i.e., 90, 150, or 300 mins/week) will be tested. All doses will consist of individualized walking delivered up to 7 times per week delivered throughout treatment.

06

What researchers measure

Primary outcomes

  1. proportion of patients achieving (ratio of delivered to planned treatment) RDI ≥ 90%

    RDI (%) will be calculated as the ratio of delivered to planned dose intensity (delivered dose intensity/planned dose intensity).

    Time frame: 5 years

07

Study locations

8 of 8 sites recruiting
  • Hartford Healthcare Alliance (Data Collection Only)
    Hartford, Connecticut 06102, United States
    Recruiting
    • Jaykumar Thumar, MD · Contact(860) 676-7000
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Jessica Scott, PhD · Contact646-888-8103
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Jessica Scott, PhD · Contact646-888-8103
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Jessica Scott, PhD · Contact646-888-8103
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Jessica Scott, PhD · Contact646-888-8103
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Jessica Scott, PhD · Contact646-888-8103
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Jessica Scott, PhD · Contact646-888-8103
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
    Rockville Centre, New York 11553, United States
    Recruiting
    • Jessica Scott, PhD · Contact646-888-8103
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Mar 2027, 46 months after the start.

Of 55 phase 2 interventional studies under Gastrointestinal Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 73. This study's planned 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
Mar 29, 2023
StartActual
Apr 28, 2023
Primary completionEst.
Mar 1, 2027
CompletionEst.
Apr 18, 2027
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05789485
Responsible party
Sponsor
First posted
Mar 29, 2023
Start date
Apr 28, 2023
Primary completion
Mar 1, 2027 (estimated)
Completion
Apr 18, 2027 (estimated)
Last update
Aug 25, 2026

Study contacts

Jessica Scott, PhD
Contact
scottj1@mskcc.org
646-888-8103
Andrea Cercek, MD
Contact
646-888-4189
Jessica Scott, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion